Welcome to our dedicated page for Candel Therapeutics SEC filings (Ticker: CADL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Candel Therapeutics, Inc. filings document a clinical-stage oncology company developing multimodal biological immunotherapies and reporting as a Nasdaq-listed issuer of common stock. Its proxy materials cover director elections, auditor ratification and annual-meeting voting matters, while Form 8-K reports furnish operating and financial results and research-and-development presentations.
Other filings disclose material agreements and capital-structure matters, including term-loan financing and facility lease amendments, along with clinical and regulatory disclosures tied to aglatimagene besadenovec and linoserpaturev. The filing record also reflects governance matters, shareholder voting mechanics and exhibit-based disclosures for key corporate actions.
Candel Therapeutics, Inc. director Radhakrishnan Maha received a grant of stock options covering 32,000 shares of common stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036.
The option is subject to time-based vesting. All 32,000 underlying shares vest and become exercisable on the earlier of June 23, 2027 or the date of the company’s next annual stockholder meeting, with vesting ending if the director leaves the board unless the board decides otherwise.
Candel Therapeutics director Nicoletta Loggia received a grant of stock options to buy 32,000 shares of common stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036. Following this grant, she holds options covering 32,000 shares.
The award is subject to time-based vesting. The options vest and become exercisable on the earlier of June 23, 2027 or the date of the next Annual Meeting of Stockholders, with vesting stopping if she leaves the board unless the board decides otherwise.
Candel Therapeutics director Joseph C. Papa received a grant of stock options, giving him the right to buy 32,000 shares of common stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036.
The award is subject to time-based vesting. All 32,000 underlying shares vest and become exercisable on the earlier of June 23, 2027 or the date of the next annual meeting of stockholders, as long as he continues serving on the board. Following this grant, he holds 32,000 stock options directly.
Candel Therapeutics director Edward J. Benz Jr. received a grant of stock options covering 32,000 shares of common stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036.
The award is subject to time-based vesting, becoming exercisable on the earlier of June 23, 2027 or the next Annual Meeting of Stockholders, as long as he continues serving on the board unless the board decides otherwise. Following this grant, he holds 32,000 stock options directly.
Candel Therapeutics director Christopher Martell received a grant of stock options for 32,000 shares of Common Stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036.
The award is subject to time-based vesting and will vest and become exercisable on the earlier of June 23, 2027 or the date of the next Annual Meeting of Stockholders, with vesting ceasing if he leaves the board unless the board decides otherwise. After this grant, he holds 32,000 options directly.
Candel Therapeutics director Renee Gaeta received a grant of 32,000 stock options to buy common shares at an exercise price of $9.08. These options were awarded as compensation, not through open-market trading.
The options use time-based vesting and become exercisable on the earlier of June 23, 2027 or the company’s next Annual Meeting of Stockholders, with vesting stopping if she leaves the board unless the board decides otherwise. The options expire on June 23, 2036, and following this grant she holds 32,000 options directly.
Candel Therapeutics director Gary J. Nabel received a grant of stock options covering 32,000 shares of common stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036. These options are subject to time-based vesting and will vest and become exercisable on the earlier of June 23, 2027 or the date of the company’s next annual meeting of stockholders. Vesting stops if he ceases serving on the board, unless the board determines that vesting should continue.
Candel Therapeutics director Diem Nguyen received a stock option grant for 32,000 shares of common stock. The options have an exercise price of $9.0800 per share and expire on June 23, 2036. They vest upon the earlier of June 23, 2027 or the company’s next annual stockholder meeting, so long as Nguyen continues serving on the board.
Candel Therapeutics director Paul B. Manning received a grant of stock options covering 32,000 shares of common stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036. Following this award, he holds 32,000 stock options directly.
The option is subject to time-based vesting. The underlying shares vest and become exercisable on the earlier of June 23, 2027 or the date of the next Annual Meeting of Stockholders, and vesting stops if he leaves the board unless the board determines otherwise.
Candel Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on June 23, 2026. As of April 24, 2026, there were 73,270,239 outstanding shares of voting common stock entitled to vote at the meeting.
Stockholders elected four Class II directors to serve until the 2029 annual meeting: Edward J. Benz, Jr., M.D., Paul B. Manning, Maha Radhakrishnan, M.D., and Paul Peter Tak, M.D., Ph.D., FMedSci. Support ranged from 24,897,348 to 31,591,618 votes "for," with broker non-votes of 22,175,525 for each nominee.
Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 53,543,020 votes for, 238,508 against, and 87,967 abstentions. No other matters were submitted for a vote.